StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV - Free Report) in a report released on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company's stock.
MediciNova Price Performance
NASDAQ MNOV traded up $0.03 on Tuesday, reaching $1.81. 10,185 shares of the company's stock traded hands, compared to its average volume of 39,234. The stock has a market cap of $88.77 million, a PE ratio of -10.65 and a beta of 0.75. MediciNova has a 12 month low of $1.12 and a 12 month high of $2.16. The stock has a 50-day simple moving average of $1.71 and a 200 day simple moving average of $1.49.
MediciNova (NASDAQ:MNOV - Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, analysts anticipate that MediciNova will post -0.23 EPS for the current year.
MediciNova Company Profile
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
